NCT06337617View on ClinicalTrials.gov

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

CompletedOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

June 29, 2023

Study Completion Date

June 29, 2023

Conditions
BRAF V600 Mutation Positive Melanoma
Trial Locations (1)

201203

Novartis, Shanghai

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT06337617 - A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma | Biotech Hunter | Biotech Hunter